文献速递胰腺与胆道疾病消化内镜消化道肿瘤与早癌

阿司匹林暴露与恶性远端胆道梗阻金属支架通畅性的关联:一项大型国际多中心倾向评分匹配研究

Aspirin exposure and its association with metal stent patency in malignant distal biliary obstruction: a large international multicenter propensity score-matched study.
PubMed 文献 · Gastrointest Endosc · 2023-11-10

这项在加拿大9个中心和美國1个中心开展的多中心回顾性队列研究纳入2014年1月至2019年12月因恶性远端胆道梗阻行ERCP并置入自膨式金属支架的患者,分为阿司匹林暴露组与未暴露组,经倾向评分匹配后各248例分析。结果显示阿司匹林暴露未降低支架功能障碍风险(HR 1.25;95%CI 0.96-1.63),胰腺癌病因预测支架功能障碍(HR 1.36;95%CI 1.15-1.61),而癌症治疗具有保护作用(HR 0.73;95%CI 0.55-0.96)。

要点

  • 匹配后阿司匹林暴露组与未暴露组各248例,支架功能障碍风险无显著差异(HR 1.25;95%CI 0.96-1.63)。
  • 胰腺癌病因是支架功能障碍的独立预测因素(HR 1.36;95%CI 1.15-1.61)。
  • 癌症治疗对支架功能障碍具有保护作用(HR 0.73;95%CI 0.55-0.96)。

核心结论

  • 在这项使用倾向评分匹配的大型多中心研究中,长期阿司匹林暴露未能保护恶性远端胆道梗阻患者免于支架功能障碍。
  • 分析显示胰腺癌病因是支架功能障碍的独立预测因素,而癌症治疗具有保护作用。

研究设计与样本

  • 多中心回顾性队列研究,在加拿大9个中心和美国1个中心开展。
  • 纳入2014年1月至2019年12月因恶性远端胆道梗阻行ERCP并置入自膨式金属支架的患者。
  • 分为阿司匹林暴露组(ASA-E)和阿司匹林未暴露组(ASA-U),采用倾向评分匹配限制选择偏倚。
  • 匹配变量为年龄、性别、肿瘤分期和金属支架类型。
  • 评估1396例患者,经倾向评分匹配后分析496例(ASA-E组248例,ASA-U组248例)。

主要发现

  • ASA-E组临床成功率为82.2%,ASA-U组为81.2%(P = .80)。
  • 184例患者发生支架功能障碍,ASA-E组平均支架通畅时间为229.9 ± 306.2天,ASA-U组为245.4 ± 241.4天(P = .52)。
  • 多变量分析中,阿司匹林暴露未保护 against 支架功能障碍(HR 1.25;95%CI 0.96-1.63)。
  • 胰腺癌病因预测支架功能障碍(HR 1.36;95%CI 1.15-1.61)。
  • 癌症治疗具有保护作用(HR 0.73;95%CI 0.55-0.96)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Stent dysfunction is common after ERCP with self-expandable metal stent (SEMS) insertion for malignant distal biliary obstruction (MDBO). Chronic aspirin (acetylsalicylic acid; ASA) exposure has been previously shown to potentially decrease this risk. We aim to further ascertain the protective effect of ASA and to identify other predictors of stent dysfunction. METHODS: This multicenter retrospective cohort study was conducted at 9 sites in Canada and 1 in the United States. Patients with MDBO who underwent ERCP with SEMS placement between January 2014 and December 2019 were included and divided into 2 cohorts: ASA exposed (ASA-E) and ASA unexposed (ASA-U). Propensity-score matching (PSM) was performed to limit selection bias. Matched variables were age, sex, tumor stage, and type of metal stent. The primary outcome was the hazard rate of stent dysfunction. A multivariable Cox proportional hazards model was used to identify independent predictors of stent dysfunction. RESULTS: Of 1396 patients assessed, after PSM 496 patients were analyzed (248 ASA-E and 248 ASA-U). ERCP with SEMS placement was associated with a high clinical success of 82.2% in ASA-E and 81.2% in ASA-U cohorts (P = .80). One hundred eighty-four patients had stent dysfunction with a mean stent patency time of 229.9 ± 306.2 days and 245.4 ± 241.4 days in ASA-E and ASA-U groups, respectively (P = .52). On multivariable analysis, ASA exposure did not protect against stent dysfunction (hazard ratio [HR], 1.25; 95% confidence interval [CI], .96-1.63). An etiology of pancreatic cancer (HR, 1.36; 95% CI, 1.15-1.61) predicted stent dysfunction, whereas cancer therapy was protective (HR, .73; 95% CI, .55-.96). Chronic ASA use was not associated with an increased risk for adverse events including bleeding, post-ERCP pancreatitis, and perforation. CONCLUSIONS: In this large, multicenter study using PSM, chronic exposure to ASA did not protect against stent dysfunction in MDBO. Instead, the analysis revealed that the etiology of pancreatic cancer was an independent predictor of stent dysfunction and cancer therapy was protective.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Candido K, Bouchard S, Hansen-Barkun C, et al. Aspirin exposure and its association with metal stent patency in malignant distal biliary obstruction: a large international multicenter propensity score-matched study. Gastrointest Endosc. 2023. PMID: 37951281. doi:10.1016/j.gie.2023.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。